RYMTI 50 MG / 1 ML
ETANERCEPT : 50 MG / 1 ML · DIN 02530295 · LUPIN PHARMA CANADA LIMITED
Health Canada status: MARKETED
What is RYMTI?
RYMTI 50 MG / 1 ML contains ETANERCEPT : 50 MG / 1 ML. It is listed in the Health Canada Drug Product Database under DIN 02530295, held by LUPIN PHARMA CANADA LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 05-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RYMTI used for?
RYMTI (etanercept) is indicated for: treatment of moderately to severely active rheumatoid arthritis (RA) in adults; reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years; reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA); reducing signs and symptoms of active ankylosing spondylitis (AS); treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy; and treatment of pediatric patients ages 4 to 17 years with chronic severe PsO who are candidates for systemic therapy or phototherapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02530295 |
|---|---|
| Brand name | RYMTI |
| Generic / active ingredient | ETANERCEPT : 50 MG / 1 ML |
| Manufacturer | LUPIN PHARMA CANADA LIMITED |
| Strength | 50 MG / 1 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L04AB01 ETANERCEPT |
| AHFS class | 90:24.16.92 |
| Biosimilar | Yes |
| Health Canada status | MARKETED |
| Status date | 05-Apr-2024 |
| Original market date | 2024-04-05 00:00:00 |
How is it stored and handled?
null
How is it supplied?
RYMTI single-use prefilled syringes are available in 25 mg (0.5 mL of a 50 mg/mL solution of etanercept) and 50 mg (1.0 mL of a 50 mg/mL solution of etanercept) dosage strengths. RYMTI single-use prefilled autoinjectors are available in a 50 mg (1.0 mL of a 50 mg/mL solution of etanercept) dosage strength.
What can be used instead?
Other Canadian products sharing ATC code L04AB01 ETANERCEPT. 8 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BRENZYS | 50 MG | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02455323 |
| BRENZYS | 50 MG | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02455331 |
| ENBREL | 50 MG | SOLUTION | IMMUNEX CORPORATION | MARKETED | DIN 02274728 |
| ERELZI | 25 MG / 0.5 ML | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02462877 |
| ERELZI | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02462850 |
| ERELZI | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02462869 |
| RYMTI | 50 MG / 1 ML | SOLUTION | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02530309 |
| ENBREL | 1 ML | LIQUID ; POWDER FOR SOLUTION ; KIT | IMMUNEX CORPORATION | CANCELLED POST MARKET | DIN 02242903 |
| RYMTI | 25 MG / 0.5 ML | SOLUTION | LUPIN PHARMA CANADA LIMITED | APPROVED | DIN 02530287 |
Who else supplies ETANERCEPT worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ETANERCEPT appears in 684 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.